Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Opexa Therapeutics logo — company profile

Opexa Therapeutics

Founded 1986 United States The Woodlands, United States 24 employees Post-IPO Debt Total: $5.84M Biotechnology, Health and Wellness

General Information

Company Name Opexa Therapeutics
Founded Year 1986
Location United States The Woodlands, United States
Employees 24
Industries Biotechnology, Health and Wellness
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Opexa Therapeutics. To contact Opexa Therapeutics, visit opexatherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Opexa Therapeutics compare?

A PDF of Opexa Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Opexa Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Opexa Therapeutics

Opexa Therapeutics is a publicly traded biotechnology company (NASDAQ: OPXA) founded in 1986 and based in the United States. The company is dedicated to developing personalized immunotherapies for major illnesses, including multiple sclerosis and other autoimmune diseases, utilizing their proprietary T-cell technology. Their leading therapy candidate, Tcelna, is a personalized T-cell immunotherapy in Phase IIb clinical development for the treatment of Secondary Progressive Multiple Sclerosis. Opexa is expecting top-line results from the Abili-T trial in the early 4th quarter of 2016. Their mission is to lead the field of Precision Immunotherapy by aligning the interests of patients, employees, and shareholders. The company received a $650.00K post-IPO debt investment on 19 February 2013. Opexa Therapeutics continues to show promise in the biotechnology space with its innovative approach to treating debilitating diseases.

Business keywords: immunotherapy, T-cell technology, multiple sclerosis, autoimmune diseases, neuromyelitis optica, Phase IIb clinical development, Tcelna, Precision Immunotherapy, Abili-T trial, publicly traded, NASDAQ, personalized therapies, Top-line results, Secondary Progressive Multiple Sclerosis

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $650.00K -
19 Feb 2013
Post IPO Debt $4.09M -
27 Jul 2012
Post IPO Equity $1.10M -
25 Apr 2009

Opexa Therapeutics Alternatives & Competitors

View All Alternatives
Opexa Therapeutics vs
Immunic Therapeutics
Immunic Therapeutics United States

Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and...

Post-IPO Equity
91 employees
Biotechnology, Health and Wellness
Opexa Therapeutics vs
Imcyse SA
Imcyse SA Belgium

Pioneering the development of Imotopes™ to prevent, stop and potentially cure autoimmune diseases

Series B
17 employees
Biotechnology, Health and Wellness
Opexa Therapeutics vs
Tmunity Therapeutics
Tmunity Therapeutics

Pioneering the future of immunotherapy through innovative T cell engineering to tackle a diverse arr...

Acquired
12 employees
Biotechnology, Health Care
View all alternatives

FAQ About Opexa Therapeutics

Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases, such as neuromyelitis optica. These therapies...
Opexa Therapeutics was founded in 1986.
Opexa Therapeutics is headquartered in The Woodlands, United States.
Opexa Therapeutics operates in Biotechnology and Health and Wellness. Its work centres on immunotherapy, T-cell technology, multiple sclerosis and autoimmune diseases.
Opexa Therapeutics has approximately 24 employees.
Opexa Therapeutics has completed 3 funding rounds, raising a total of $5.84M. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Opexa Therapeutics include Immunic Therapeutics, Imcyse SA, Tmunity Therapeutics, PDC*line Pharma, Cogent Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Opexa Therapeutics and Immunic Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Opexa Therapeutics, https://bouncewatch.com/company/opexa-therapeutics, updated 28 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout